SCHEMBL8215841

SCHEMBL8215841

Cc1cccc2c1C=CCO2

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 8/20 0.46
CYP1B1 Q16678 6/20 0.46
CYP2B6 P20813 1/20 0.42
HTR2C P28335 1/20 0.41
CYP1A1 P04798 6/20 0.40
MTNR1A P48039 2/20 0.38
MTNR1B P49286 1/20 0.38
MAP3K14 Q99558 1/20 0.37
CA1 P00915 2/20 0.32
CA9 Q16790 2/20 0.32
CYP2A6 P11509 1/20 0.31
CA2 P00918 1/20 0.30
CA7 P43166 1/20 0.30
ABCG2 Q9UNQ0 1/20 0.30
ITGB2 P05107 1/20 0.30
ICAM1 P05362 1/20 0.30
ITGAL P20701 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8404603 0.76 CYP1A2 (0.50) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL5541990 0.76 CYP2B6 (0.46) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL275271 0.76 CYP2B6 (0.46) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL2008458 0.76 CYP2B6 (0.42) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL14653042 0.76 CYP2B6 (0.42) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL5541390 0.76 CYP2B6 (0.42) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL27788895 0.76 CYP2B6 (0.40) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL9620021 0.76 CYP2B6 (0.40) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
Hydrochloric Acid SCHEMBL29164105 0.74 CYP2B6 (0.41) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A
SCHEMBL13113614 0.73 CYP2B6 (0.43) CYP1A2CYP1B1CYP2B6CYP1A1MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283368-B2 Selective ligands for the dopamine 3 (D3) receptor and methods of using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-09 US disclosed
US-8283368-B2 Selective ligands for the dopamine 3 (D3) receptor and methods of using the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2012-10-09 US disclosed
US-20110319362-A1 STAT3 LIGANDS AND THERAPEUTIC USES THEREOF WANG SHAOMENG (US) 2011-12-29 US disclosed
US-20110319362-A1 STAT3 LIGANDS AND THERAPEUTIC USES THEREOF WANG SHAOMENG (US) 2011-12-29 US disclosed
US-20110184033-A1 Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2011-07-28 US disclosed
WO-2010077589-A2 STAT3 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN OFFICE OF TECHNOLOGY TRANSFER (US) 2010-07-08 WO disclosed
WO-2008038251-A2 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-03 WO disclosed
CN-1860112-A 3-amino chroman and 2-amino tetralin derivatives WYETH CORP (US) 2006-11-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184033-A1 Selective Ligands for the Dopamine 3 (D3) Receptor and Methods of using the Same DRD3, HTR3C, HTR3A CYP1A2 1924/4885CYP1B1 1995/4885CYP2B6 1176/4885
US-20110319362-A1 STAT3 LIGANDS AND THERAPEUTIC USES THEREOF STAT3, JAK2, STAT6 CYP1A2 4602/4885CYP1B1 4585/4885CYP2B6 4287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.